TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

UBIP

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: US

Quick snapshot

UBIP

ST13

US500000097470141

Class

5, 42

Filing

97470141

Registration

7739637

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

41

Latest update

03/25/2025

Classification

Registered

Trademark type

Combined

Nice classes

5, 42

Filing date

06/22/2022

Registration date

03/25/2025

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/25/2025

Last transaction

03/25/2025

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

2022-11-00

First use in commerce

2022-11-00

Drawing code

3

Owner type

03

Owner location

Hsinchu County, TW

Examiner

FRIEDMAN, LESLEE

Law office

N20

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the stylized letters "UBIP." A stylized globe forms a portion of the letter "P" in "UBIP".

Holders and representatives

Holders

UBI Pharma Inc.

Representatives

Joe McKinney Muncy MUNCY, GEISSLER, OLDS & LOWE, P.C.

Technical classification

Nice Classes

Class 5Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Antibiotics; Pre-filled syringes for medical purposes being syringes sold filled with pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Medicines for human purposes for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Contrast medium for medical use being contrast media for in vivo imaging; Ointments for pharmaceutical purposes being anti-biotic, anti-infective, and anti-inflammatory ointments; Poultices for pharmaceutical purposes being anti-biotic, anti-infective, and anti-inflammatory poultices; Western medicine, namely, pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Active pharmaceutical ingredients (APIs) for Western Medicine being pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Vitamin preparations; antiviral drug; biological preparations for medical purposes being biological preparations for the treatment of cancers, infections, metabolic diseases, neurological disorders; Hormones for medical purposes; Medicated skin lotions for pharmaceutical purposes; Medicinal drinks; Vaccines; chemico-pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, neurological disorders; Albuminous preparations for medical purposes, namely, pharmaceutical preparations featuring albumin peptides, proteins and complexes thereof for the treatment of cancers, infections, metabolic diseases, and neurological disorders; biological reagent for medical purposes; test reagent for medical purposes; Diagnostic preparations for medical purposes; Diagnostic biomarker reagents for medical purposes

Class 42

Providing research and development in the field of biological and pharmaceutical scientific research and development; Biological research; Bacteriological research; Clinical lab test of medical reagent being providing reagent sample testing for others for scientific research purposes; Clinical trials, namely, scientific research in the nature of conducting clinical trials for others; Research and analysis of medical reagent being medical research; medical research; Research and development of new products for others; Technical project studies being conducting of feasibility studies in the field of new technologies; Technical writing; Industrial analysis and research service in the field of pharmaceutical sciences; Rental of laboratory instruments; Scientific laboratory services; Technological consultancy in the field of biological and pharmaceutical manufacturing processes; scientific research and technological research in the field of biological and pharmaceutical manufacturing processes; culturing of cells for others for scientific research purposes

Publications

History of USPTO decisions and trademark events.

41 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

03/25/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

03/25/2025

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

03/03/2025

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

03/03/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/14/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/14/2025

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

02/14/2025

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

11/15/2024

GNFR

FINAL REFUSAL E-MAILED

11/15/2024

CNFR

SU - FINAL REFUSAL - WRITTEN

11/15/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/22/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/22/2024

ALIE

ASSIGNED TO LIE

10/22/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

07/11/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

04/12/2024

GNRT

NON-FINAL ACTION E-MAILED

04/12/2024

CNRT

SU - NON-FINAL ACTION - WRITTEN

04/12/2024

SUPC

STATEMENT OF USE PROCESSING COMPLETE

03/16/2024

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

03/11/2024

IUAF

USE AMENDMENT FILED

02/20/2024

EISU

TEAS STATEMENT OF USE RECEIVED

02/20/2024

DOCK

ASSIGNED TO EXAMINER

10/23/2023

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

09/12/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

07/18/2023

PUBO

PUBLISHED FOR OPPOSITION

07/18/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

06/28/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

06/08/2023

XAEC

EXAMINER'S AMENDMENT ENTERED

06/08/2023

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

06/08/2023

GNEA

EXAMINERS AMENDMENT E-MAILED

06/08/2023

CNEA

EXAMINERS AMENDMENT -WRITTEN

06/08/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/09/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/09/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

05/09/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

04/11/2023

GNRT

NON-FINAL ACTION E-MAILED

04/11/2023

CNRT

NON-FINAL ACTION WRITTEN

04/11/2023

DOCK

ASSIGNED TO EXAMINER

04/04/2023

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

07/12/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/11/2022

NWAP

NEW APPLICATION ENTERED

06/25/2022

Continuous trademark protection

Get notified about every new filing that threatens UBIP or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.